Gastrointestinal Cancers

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian.

Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts.

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.

The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the investigative immunotherapy NG-350A.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.

I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient mentorship.

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.

After being diagnosed with colon cancer, I learned the life-changing lessons of self-love, stepping out of my comfort zone and embracing positive thinking.

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim analysis and potential regulatory approvals.

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less invasive or complex surgeries.

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

In the LEAP-015 trial, Keytruda and Lenvima plus chemo did not meet the primary end point of overall survival in HER2– gastroesophageal adenocarcinoma.

In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Despite the initial shock and challenges, I found strength and support within the community of single parents.

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.